Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-09-11Actual
Enrollment · participants135Actual
Source updated2023-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.